”’Certolizumab pegol”’, sold under the brand name ”’Cimzia”’, is a [[biopharmaceutical]] medication for the treatment of [[Crohn’s disease]],<ref name=”pmid17634458″>{{cite journal | vauthors = Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S | display-authors = 6 | title = Certolizumab pegol for the treatment of Crohn’s disease | journal = The New England Journal of Medicine | volume = 357 | issue = 3 | pages = 228–238 | date = July 2007 | pmid = 17634458 | doi = 10.1056/NEJMoa067594 | doi-access = free | pmc = 3187683 }}</ref><ref>{{cite journal | vauthors = Goel N, Stephens S | title = Certolizumab pegol | journal = mAbs | volume = 2 | issue = 2 | pages = 137–147 | year = 2010 | pmid = 20190560 | pmc = 2840232 | doi = 10.4161/mabs.2.2.11271 }}</ref> [[rheumatoid arthritis]], [[psoriatic arthritis]] and [[ankylosing spondylitis]]. It is a fragment of a [[monoclonal antibody]] specific to [[tumor necrosis factor alpha]] (TNF-α) and is manufactured by [[UCB (company)|UCB]].<ref name=”pmid15934837″>{{cite journal | vauthors = Kaushik VV, Moots RJ | title = CDP-870 (certolizumab) in rheumatoid arthritis | journal = Expert Opinion on Biological Therapy | volume = 5 | issue = 4 | pages = 601–606 | date = April 2005 | pmid = 15934837 | doi = 10.1517/14712598.5.4.601 | s2cid = 21974683 }}</ref><ref name=”Cimzia Label and Approval History”>{{cite web | title=Drug Approval Package: Cimzia (Certolizumab Pegol) NDA #125160 | website=U.S. [[Food and Drug Administration]] (FDA) | date=December 24, 1999 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125160s000TOC2.cfm | archive-url=https://web.archive.org/web/20150215072924/http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125160s000TOC2.cfm | url-status=dead | archive-date=February 15, 2015 | access-date=July 18, 2020}}</ref><ref name=”Cimzia FDA label”>{{cite web | title=Cimzia- certolizumab pegol kit Cimzia- certolizumab pegol injection, solution | website=DailyMed | date=April 24, 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4c2c9dc-a0bb-4d64-a667-a67ebe88392d | access-date=July 18, 2020}}</ref>
”’Certolizumab pegol”’, sold under the brand name ”’Cimzia”’, is a [[biopharmaceutical]] medication for the treatment of [[Crohn’s disease]],<ref name=”pmid17634458″>{{cite journal | vauthors = Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S | display-authors = 6 | title = Certolizumab pegol for the treatment of Crohn’s disease | journal = The New England Journal of Medicine | volume = 357 | issue = 3 | pages = 228–238 | date = July 2007 | pmid = 17634458 | doi = 10.1056/NEJMoa067594 | doi-access = free | pmc = 3187683 }}</ref><ref>{{cite journal | vauthors = Goel N, Stephens S | title = Certolizumab pegol | journal = mAbs | volume = 2 | issue = 2 | pages = 137–147 | year = 2010 | pmid = 20190560 | pmc = 2840232 | doi = 10.4161/mabs.2.2.11271 }}</ref> [[rheumatoid arthritis]], [[psoriatic arthritis]] and [[ankylosing spondylitis]]. It is a fragment of a [[monoclonal antibody]] specific to [[tumor necrosis factor alpha]] (TNF-α) and is manufactured by [[UCB (company)|UCB]].<ref name=”pmid15934837″>{{cite journal | vauthors = Kaushik VV, Moots RJ | title = CDP-870 (certolizumab) in rheumatoid arthritis | journal = Expert Opinion on Biological Therapy | volume = 5 | issue = 4 | pages = 601–606 | date = April 2005 | pmid = 15934837 | doi = 10.1517/14712598.5.4.601 | s2cid = 21974683 }}</ref><ref name=”Cimzia Label and Approval History”>{{cite web | title=Drug Approval Package: Cimzia (Certolizumab Pegol) NDA #125160 | website=U.S. [[Food and Drug Administration]] (FDA) | date=December 24, 1999 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125160s000TOC2.cfm | archive-url=https://web.archive.org/web/20150215072924/http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125160s000TOC2.cfm | url-status=dead | archive-date=February 15, 2015 | access-date=July 18, 2020}}</ref><ref name=”Cimzia FDA label”>{{cite web | title=Cimzia- certolizumab pegol kit Cimzia- certolizumab pegol injection, solution | website=DailyMed | date=April 24, 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4c2c9dc-a0bb-4d64-a667-a67ebe88392d | access-date=July 18, 2020}}</ref>
It is on the [[WHO Model List of Essential Medicines|World Health Organization’s List of Essential Medicines]].<ref name=”WHO23rd“>{{cite book | vauthors = ((World Health Organization)) | title = The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) | year = 2023 | hdl = 10665/371090 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2023.02 | hdl-access=free }}</ref>
is on the [[WHO Model List of Essential Medicines|World Health Organization’s List of Essential Medicines]].<ref name=””>{{cite book | vauthors = ((World Health Organization)) | title = The selection and use of essential medicines : of list | year = | hdl = 10665/ | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | hdl-access=free }}</ref>
;Rheumatoid arthritis: Certolizumab appears beneficial in those with [[rheumatoid arthritis]].<ref name=Cochrane2017>{{cite journal | vauthors = Ruiz Garcia V, Burls A, Cabello JB, Vela Casasempere P, Bort-Marti S, Bernal JA | title = Certolizumab pegol (CDP870) for rheumatoid arthritis in adults | journal = The Cochrane Database of Systematic Reviews | volume = 2017 | issue = 9 | pages = CD007649 | date = September 2017 | pmid = 28884785 | pmc = 6483724 | doi = 10.1002/14651858.CD007649.pub4 }}</ref>
;Rheumatoid arthritis: Certolizumab appears beneficial in those with [[rheumatoid arthritis]].<ref name=Cochrane2017>{{cite journal | vauthors = Ruiz Garcia V, Burls A, Cabello JB, Vela Casasempere P, Bort-Marti S, Bernal JA | title = Certolizumab pegol (CDP870) for rheumatoid arthritis in adults | journal = The Cochrane Database of Systematic Reviews | volume = 2017 | issue = 9 | pages = CD007649 | date = September 2017 | pmid = 28884785 | pmc = 6483724 | doi = 10.1002/14651858.CD007649.pub4 }}</ref>
